halopemide has been researched along with N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, MD; Arteaga, CL; Brown, HA; Buck, JR; Cho, HP; Criswell, TL; Lindsley, CW; Scott, SA; Selvy, PE; Thomas, AL | 1 |
| Armstrong, MD; Brown, HA; Buck, JR; Lavieri, R; Lewis, JA; Lindsley, CW; Scott, SA; Selvy, PE; Stoops, SL | 1 |
2 other study(ies) available for halopemide and N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide
| Article | Year |
|---|---|
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Topics: Breast Neoplasms; Drug Design; Enzyme Inhibitors; Humans; Isoenzymes; Neoplasm Invasiveness; Phospholipase D | 2009 |
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
Topics: Benzimidazoles; Cell Line; Domperidone; Drug Design; Enzyme Inhibitors; Halogenation; Humans; Phospholipase D; Protein Isoforms; Structure-Activity Relationship; Substrate Specificity | 2009 |